ArticleJournal of molecular modeling2026
Rational hybrid design and computational characterization of PA-Hyb1: a novel peptide inhibitor targeting the MexB efflux pump in Pseudomonas aeruginosa.
Article in Journal of molecular modeling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextThe MexAB-OprM efflux pump is a primary driver of multidrug resistance in Pseudomonas aeruginosa. While antimicrobial peptides (AMPs) offer a promising alternative to small-molecule inhibitors, understanding their dynamic interactions with large, multi-domain membrane transporters like MexB requires rigorous computational modeling. Rational hybrid peptide design combined with physics-based Molecular Dynamics simulations provides a strategic pathway to optimize AMP efficacy and predict binding stability prior to experimental synthesis. Ten hybrid peptides were designed and screened in silico for toxicity and physicochemical properties. The lead candidate, PA-Hyb1, exhibited a stable α-helical conformation and favorable safety profiles. During extended MD simulations, PA-Hyb1 displayed structural flexibility, anchoring its hydrophobic N-terminus via persistent π-π stacking with Phe178/Phe610, while its cationic C-terminus dynamically scanned acidic vestibule residues. MM/PBSA calculations over the equilibrated trajectory (from 300 to 500 ns) yielded a binding enthalpy of -28.5 ± 2.4 kcal/mol. This interaction energy was significantly superior to levofloxacin (-14.2 ± 1.8 kcal/mol; p < 0.0001) and outperformed scrambled and parent fragment controls, closely approaching the rigid small-molecule inhibitor D13-9001 (-30.1 ± 1.8 kcal/mol), despite the inherent entropic penalty of peptide flexibility. The computational pipeline successfully identified PA-Hyb1 as a high-affinity, sequence-specific candidate for MexB inhibition, establishing a strong rationale for its in vitro synthesis and validation. These binding-mode findings were obtained in a DPPC/POPE bilayer used as a simplified membrane-mimetic system rather than the native Pseudomonas aeruginosa inner-membrane lipid composition (predominantly phosphatidylethanolamine, phosphatidylglycerol, and cardiolipin), and outer-membrane penetration by PA-Hyb1 was not evaluated; these limitations, together with a preliminary host-safety-only ADMET screen, temper the translational claims below and are discussed further in Sect. 4.1.
methodsTen hybrid peptides were designed by fusing functional motifs from Cecropin A, Magainin 2, and LL-37. Candidates were screened in silico for toxicity and physicochemical properties. The lead candidate, PA-Hyb1, was structurally modeled using PEP-FOLD4 and energy minimized under the CHARMM36m force field. Molecular docking (AutoDock Vina) targeted the distal binding pocket (Cavity C3) of MexB (PDB ID: 6IIA). To evaluate dynamic stability and binding thermodynamics, 500-ns all-atom Molecular Dynamics simulations were conducted in an explicit asymmetric DPPC/POPE lipid bilayer. Binding affinities were quantified using MM/PBSA free energy calculations and rigorously compared against a scrambled sequence control, parent fragments, levofloxacin, and the D13-9001 reference inhibitor.
Indexed as
Identifiers
42730777What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.